Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 10, 2005. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to reporting specific equity transactions and does not contain financial performance data.
Material Changes
The primary material change reported is a transfer of 5,006 Ordinary Shares from the GlaxoSmithKline Employee Trust ("the GSK Trust") to participants in the SmithKline Beecham Employee Share Option Plan 1991. This transaction occurred on February 9, 2005, and the company was advised of it on February 10, 2005.
Management Commentary and Risks
The filing notes that the GSK Trust is a discretionary trust where all current and former employees are potential beneficiaries. Consequently, three directors—Dr J-P Garnier, Dr T Yamada, and Mr J D Coombe—hold an interest in the shares held by the trust in the same manner as other employees. No specific risks, contingencies, or unusual items regarding operations were disclosed in this text.
Investor Verification Points
- Verify the total number of shares held by the GSK Trust following the transfer of 5,006 shares.
- Confirm the specific allocation of the transferred shares among the three named directors versus other plan participants.
- Review the full terms of the SmithKline Beecham Employee Share Option Plan 1991 to understand vesting conditions.